- Previous Close
4,036.05 - Open
4,055.00 - Bid --
- Ask --
- Day's Range
3,975.55 - 4,058.00 - 52 Week Range
3,865.00 - 6,451.15 - Volume
13,753 - Avg. Volume
49,215 - Market Cap (intraday)
185.157B - Beta (5Y Monthly) 0.22
- PE Ratio (TTM)
30.11 - EPS (TTM)
134.40 - Earnings Date May 15, 2025 - May 19, 2025
- Forward Dividend & Yield 35.00 (0.87%)
- Ex-Dividend Date Aug 21, 2024
- 1y Target Est
5,623.33
Pfizer Limited engages in manufacturing, marketing, trading, and export of pharmaceutical products in India and internationally. It offers its products in various therapeutic areas, including neuro/CNS, hormones, cardiovascular, haemophilia, anti-infectives, gynecology, pain/analgesics, orthopedic, oncology, urology, anti-parasitic, gastro intestinal, vaccines, and respiratory, as well as vitamins, minerals, and nutrients. The company also offers internal medicine and anti-infectives services to hospitals and nursing homes. It serves healthcare providers, government and private hospitals, and retail pharmacies. The company sells its products through a network of independent distributors. Pfizer Limited was incorporated in 1950 and is based in Mumbai, India.
www.pfizerltd.co.in1,721
Full Time Employees
March 31
Fiscal Year Ends
Sector
Industry
Recent News: PFIZER.NS
View MorePerformance Overview: PFIZER.NS
Trailing total returns as of 4/2/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PFIZER.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PFIZER.NS
View MoreValuation Measures
Market Cap
184.64B
Enterprise Value
162.35B
Trailing P/E
30.00
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.26
Price/Book (mrq)
4.92
Enterprise Value/Revenue
7.26
Enterprise Value/EBITDA
18.03
Financial Highlights
Profitability and Income Statement
Profit Margin
27.53%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
22.36B
Net Income Avi to Common (ttm)
6.16B
Diluted EPS (ttm)
134.40
Balance Sheet and Cash Flow
Total Cash (mrq)
22.81B
Total Debt/Equity (mrq)
1.99%
Levered Free Cash Flow (ttm)
--